Best Practice & Research Clinical Haematology

Papers
(The median citation count of Best Practice & Research Clinical Haematology is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
HLA typing: A review of methodologies and clinical impact on haematopoietic cell transplantation79
The role of randomized controlled trials, registries, observational databases in evaluating new interventions49
Asparaginase dosing for obese patients with acute lymphoblastic leukemia and factors that contribute to outcomes43
Reducing barriers of access and care related to hematopoietic cell transplantation and cellular therapy: The mission-driven role of the national marrow donor program38
What are the long-term complications of pediatric ALL treatments and how can they be mitigated? Perspectives on long-term consequences of curative treatment in childhood ALL38
Coagulopathy in COVID-19 and anticoagulation clinical trials25
Allogeneic “Off-the-Shelf” CAR T cells: Challenges and advances25
Endpoint selection and evaluation in hematology studies25
“The state of the science” of childhood, adolescent and young adult Non Hodgkin Lymphoma (NHL)24
Editorial Board23
The presentation of results from studies in clinical haematology23
Take a spin: Apheresis in the care of adult leukaemia patients22
How can we improve response assessments in MDS? Strategies to improve response assessment in MDS treatment paradigms15
Biopathology of childhood, adolescent and young adult non-Hodgkin lymphoma15
Vaccine-induced immune thrombotic thrombocytopenia14
Creating a GMP cell processing program: A focus on quality and regulation14
Targeted cellular therapy for treatment of relapsed or refractory leukemia12
Cytogenomics of B-cell non-Hodgkin lymphomas: The “old” meets the “new”11
Diagnosis and management of post-transplant lymphoproliferative disease following solid organ transplantation in children, adolescents, and young adults11
What should be done and what should be avoided when comparing two treatments?11
Principles of cost-effectiveness studies and their use in haematology11
The international cooperative Gaucher group (ICCG) Gaucher registry11
Dysregulation of Protein S in COVID-1910
Editorial Board10
Applications and prospects of molecularly targeted drugs combined with CAR-T cell therapy to treat multiple myeloma10
The role of registries in hematological disorders9
Anti-GM-CSF autoantibodies in myeloid leukemias8
Prevention and treatment of COVID-19 in patients with benign and malignant blood disorders8
Hodgkin Lymphoma: A disease shaped by the tumor micro- and macroenvironment8
Corrigendum to “Precision immunomodulation: Understanding and harnessing cytokine pathways to treat and prevent immune-related adverse events (irAEs)” [Best Pract Res Clin Haematol 38 2 2025]8
Late effects and frontline treatment selection for children with non-Hodgkin lymphoma8
Human mesenchymal stem cell therapy: Potential advances for reducing cystic fibrosis infection and organ inflammation8
Is HLA-E with its receptors an immune checkpoint or an antigenic determinant in allo-HCT?8
Worldwide sources of data in haematology: Importance of clinician-biostatistician collaboration8
The analysis of multiple outcomes, multiple variables and variables selection in hematopoietic cell transplantation studies7
CAR assembly line: Taking CAR T-cell manufacturing to the next level7
Handling missing covariate data in clinical studies in haematology7
A reflection on Arnold Caplan, the father of MSC7
Editorial Board / Aims & Scope7
Recent progress in acute leukemia and myelodysplasia7
What is relative survival and what is its role in haematology?6
The current landscape: Allogeneic hematopoietic stem cell transplant for acute lymphoblastic leukemia6
Therapeutic initiatives using mesenchymal stem cells and other novel cells in hematology6
Cytokines in hematopoietic cell transplantation and related cellular therapies6
Corrigendum to “Endpoint selection and evaluation in hematology studies” [Best Pract Res Clin Haematol 36 (2023) 101479]6
CARs for lymphoma5
The most frequent HLA alleles around the world: A fundamental synopsis5
Corrigendum to “Designing and conducting a clinical trial in blood and marrow transplantation” [Best Pract Res Clin Haematol 36 (2023) 101471]5
The correlations among racial/ethnic groups, hypertriglyceridemia, thrombosis, and mortality in hospitalized patients with COVID-195
SARS-CoV-2 primary and breakthrough infections in patients with cancer: Implications for patient care5
Cytogenetics and genomics in CML and other myeloproliferative neoplasms5
Measurable residual disease in patients undergoing allogeneic transplant for acute myeloid leukemia5
Diagnosis and management of mature B-cell lymphomas in children, adolescents, and young adults5
Donor lymphocyte infusion in Acute Myeloid Leukemia5
Relevance of donor-specific HLA antibodies in hematopoietic cell transplantation5
When to use which molecular prognostic scoring system in the management of patients with MDS?5
Preface of special edition “Biostatistics in clinical haematology”5
Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents4
Cytokine therapy of acute radiation syndrome4
The Collaborative Biobank (CoBi): Donor and recipient samples & data to facilitate future research on hematopoietic cell transplantation4
COVID-19: A hematological perspective4
Shape of the art: TCR-repertoire after allogeneic hematopoietic cell transplantation4
Interfering with KIR and NKG2A immune checkpoint axes to unleash NK cell immunotherapy4
Mesenchymal stem cells in hematology: Therapeutic initiatives and future directions4
Using real-world evidence in haematology4
Diagnosis and management of rare paediatric Non-Hodgkin lymphoma4
COVID-19 and antiphospholipid antibodies4
Editorial Board / Aims & Scope4
Germline predisposition to myeloid neoplasms: Characteristics and management of high versus variable penetrance disorders4
Cytokines in transplantation tolerance3
Editorial Board3
HLA-DM and HLA-DO interplay for the peptide editing of HLA class II in healthy tissues and leukemia3
The best GVHD prophylaxis: Or at least progress towards finding it3
Editorial Board3
Designing and conducting a clinical trial in blood and marrow transplantation3
Advancing MSC therapy: The next generation of potent mesenchymal stromal cells for systemic autoimmune rheumatic diseases3
The Australian Aplastic Anaemia and other Bone Marrow Failure Syndromes Registry3
Diagnosis and management of Hodgkin lymphoma in children, adolescents, and young adults3
Redox stress in COVID-19: Implications for hematologic disorders3
Research progress of targeted BCMA CAR-T therapy for relapsed/refractory multiple myeloma antigen-negative relapse3
Cytogenetics and genomics in pediatric acute lymphoblastic leukaemia3
Natural born Killers: Harnessing NK cells to treat cancer3
Consolidation chemotherapy in AML: Are we playing with a full deck of cards?3
2.7907190322876